Today’s Research Reports on Trending Tickers: Omeros and Spectrum Pharmaceuticals
U.S. stocks retreated on Thursday after the Fed left interest rates unchanged and signaled that it would continue to tighten monetary policy at a gradual pace. The Dow Jones Industrial Average gained 0.04 percent to close at 26,191.22, while the S&P 500 Index shed 0.25 percent to close at 2,806.83. The Nasdaq Composite Index decreased 0.53 percent higher to close at 7,530.89.
Charlie Ripley, senior investment strategist at Allianz Investment Management said that, “With no press conference or expectation for policy change, most market participants viewed the November FOMC meeting as more of a non-event. Despite the headwinds of increased market volatility and tightening financial condition, the Fed appears committed to continuing the gradual process of lifting rates and removing accommodation.”
“With only minimal changes to the statement the Fed is remaining vague about policy changes going forward and likely giving the committee more optionality in a changing market environment,” he added.
RDI Initiates Coverage on:
Spectrum Pharmaceuticals, Inc.
Omeros’ stock moved 1.96% lower Thursday, to close the day at $16.02. The stock recorded a trading volume of 469,338 shares, which was below its three months average volume of 844,338 shares. In the last year, Omeros’ shares have traded in a range of 8.36 – 27.00. The share price has gained 91.63% from its 52 week low. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $17.31 is below its 200-day moving average of $19.51. Shares of Omeros have gained roughly 8.68 percent in the past month and are down 17.55 percent year-to-date.
Access RDI’s Omeros Corporation Research Report at:
On Thursday, shares of Spectrum Pharmaceuticals recorded a trading volume of 1,205,431 shares, which was below the three months average volume of 1,574,210 shares. The stock ended the day 3.02% lower at $12.84. The share price has fallen 49.23% from its 52 week high with a 52 week trading range of 11.52 – 25.29. The company’s shares are currently trading below their 200-day moving average. The stock’s 50-day moving average of $14.86 is below its 200-day moving average of $19.07. Shares of Spectrum Pharmaceuticals have fallen roughly 18.32 percent in the past month and are down 32.24 percent year-to-date.
Access RDI’s Spectrum Pharmaceuticals, Inc. Research Report at:
Our Actionable Research on Omeros Corporation (NYSE:OMER) and Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
For any questions, inquiries, or comments reach out to us directly at:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.